Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment.
Canadian Cannabis Sales Rebound In July
Statistics Canada released July retail sales for the country, with cannabis sales increasing from the June levels, up 1.6% to C$440.7 million. On a per-day basis, sales
September 20, 2024